Transgene Stock

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:55:00 2026-09-18 am EDT			5-day change	1st Jan Change
0.8600 ^EUR	-0.46%		-2.38%	-10.42%

Sep. 08	Transgene Expands ProBioGen Partnership With Additional License	MT
Sep. 03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE

Last Transcript: Transgene

Transgene SA - Special Call

Jun. 29

More transcripts

Analysts' recommendations: Transgene

Jun. 25	Oddo BHF Stays Positive on Transgene
Apr. 07	Transgene stands out following licensing agreement with NEC Bio
Nov. 27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
25-10-13	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
25-09-18	Transgene: analysts reiterate their recommendations after results

More recommendations

News in other languages: Transgene

Sep. 20	Agenda des résultats de la semaine : des valeurs moyennes françaises, Pasqal et Costco
Sep. 18	Agenda Zonebourse des résultats de sociétés : semaine du 21 au 25 septembre 2026
Sep. 08	Bourse : Eurazeo finance Mistral, les opérateurs européens veulent riposter à Starlink, Anthropic renoncerait à Decart
Sep. 08	Transgene étend sa collaboration avec ProBioGen
Sep. 08	Le yen s'énerve et anime un début de semaine soporifique

More news

Managers and Directors: Transgene

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	2023-05-31
Lucie Larguier DFI	Director of Finance/CFO	-	2024-03-26
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	2025-04-01

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	2010-07-26
Jean-Luc Bélingard BRD	Director/Board Member	76	2013-06-18
Alain Mérieux BRD	Director/Board Member	88	2006-12-31

More insiders

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

Sep. 23 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-18	€0.8600	-0.46%	21,319
26-09-17	€0.8640	+0.23%	21,983
26-09-16	€0.8620	+0.12%	21,559
26-09-15	€0.8610	-1.94%	50,271
26-09-14	€0.8780	-0.34%	51,203

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8600EUR

Average target price

1.100EUR

Spread / Average Target

+27.91%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Cap	236M 270M 222M 202M 378M 25.94B 380M 2.66B 1.03B 13.2B 1.02B 993M 42.44B	P/E 2026 *	-6.14x	P/E 2027 *	-3.91x
Enterprise Value	166M 191M 157M 143M 267M 18.32B 268M 1.88B 726M 9.32B 717M 701M 29.97B	EV / Sales 2026 *	23.1x	EV / Sales 2027 *	31.6x
Free-Float	19.4%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
CBOE	TNGp	Real-time
Boerse Muenchen	TGNA	Real-time
OTC Markets	TRGNF	Delayed
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Börse Stuttgart	TGNA	Delayed

Sep. 08	Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line	GL
Sep. 02	Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications	GL
Jul. 07	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026	GL
Jun. 25	Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026	GL
Jun. 22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	GL

1 day	-0.46%
1 week	-2.38%
Current month	+7.63%
1 month	+2.38%
3 months	+14.36%
6 months	+15.59%
Current year	-10.42%

1 week	0.86	0.88
1 month	0.78	0.97
Current year	0.7	1.03
1 year	0.7	1.5
3 years	0.53	1.82
5 years	0.53	2.99
10 years	0.53	3.79

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news: Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Price Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
8/2/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-0.46%	-2.38%	-26.50%	-52.17%	270M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+47.13%	+99.00%	70.88B
ARGENX SE	+0.39%	+2.06%	+39.38%	+78.27%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+33.27%	+16.01%	26.34B
INSMED INCORPORATED	-3.21%	-7.27%	-17.10%	+356.10%	26.21B
BIONTECH SE	-2.64%	-0.69%	-0.17%	-13.01%	24.13B
GENMAB A/S	+0.71%	+8.03%	+25.03%	-12.74%	20.72B
PHARMAESSENTIA CORPORATION	+2.12%	-5.86%	+161.58%	+329.34%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+45.54%	+172.46%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-5.51%	+849.47%	14.24B
Average	-0.24%	+1.33%	+30.27%	+182.27%	27.51B
Weighted average by Cap.	-0.28%	+1.48%	+35.62%	+148.02%

	2026 *	2027 *
Net sales	7.2M 8.27M 6.8M 6.17M 11.56M 793M 11.6M 81.24M 31.41M 403M 31.04M 30.35M 1.3B	7.2M 8.27M 6.8M 6.17M 11.56M 793M 11.6M 81.24M 31.41M 403M 31.04M 30.35M 1.3B
Net income	-38.2M -43.86M -36.06M -32.75M -61.34M -4.21B -61.56M -431M -167M -2.14B -165M -161M -6.88B	-61.6M -70.73M -58.15M -52.81M -98.92M -6.78B -99.27M -695M -269M -3.45B -266M -260M -11.1B
Net Debt	-69.2M -79.45M -65.32M -59.33M -111M -7.62B -112M -781M -302M -3.88B -298M -292M -12.47B	-7.7M -8.84M -7.27M -6.6M -12.36M -848M -12.41M -86.88M -33.59M -431M -33.2M -32.46M -1.39B